Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of LY2439821 in rheumatoid arthritis on DMARD background therapy
2009-009696-34Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ixekizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at week 12 in bDMARD-naive population. Started May 2009; status: completed.
02
Drugs
ixekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-009696-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009696-34.